LianBio APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LianBio (LIANY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.54 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-11-13
- LianBio apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $4.54M, a 4.20% decline year-over-year.
- LianBio apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $4.49M, a 0.75% decline year-over-year.
- LianBio apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $4.28M, a 8.42% decline year-over-year.
- LianBio apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $4.74M, a 118.59% increase year-over-year.
- LianBio apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $19.15M, a 121.01% increase from fiscal 2021.
- LianBio apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $8.66M, a 67.36% increase from fiscal 2020.
- LianBio apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $5.18M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2023-09-30 | $4.54M 10-Q · filed 2023-11-13 | $9.03M derived: sum of 2 quarters · filed 2023-11-13 | $13.31M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2023-06-30 | $4.49M 10-Q · filed 2023-11-13 | $8.77M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2023-03-31 | $4.28M 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | $19.15M 10-K · filed 2023-03-28 | |||
| 2022-09-30 | $4.74M 10-Q · filed 2023-11-13 | $9.27M derived: sum of 2 quarters · filed 2023-11-13 | $13.94M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $4.53M 10-Q · filed 2023-11-13 | $9.20M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $4.67M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $8.66M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $2.17M 10-Q · filed 2022-11-10 | $3.61M derived: sum of 2 quarters · filed 2022-11-10 | $5.29M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.44M 10-Q · filed 2022-11-10 | $3.12M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.67M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $5.18M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $383.00K 10-Q/A · filed 2022-01-10 | $758.00K derived: sum of 2 quarters · filed 2022-01-10 | $2.26M derived: sum of 3 quarters · filed 2022-01-10 | |
| 2020-06-30 | $375.00K 10-Q/A · filed 2022-01-10 | $1.88M derived: sum of 2 quarters · filed 2022-01-10 | ||
| 2020-03-31 | $1.50M 10-Q/A · filed 2022-01-10 |